Keyword Connections

erlotinib

Journals

8

1 PloS one

2 Oncogene

3 Journal of pharmaceutical and biomedical analysis

4 annals of surgical oncology

5 expert opinion on therapeutic targets

6 international journal of oncology

7 leukemia

8 journal of immunology (baltimore, md : 1950)

Research Groups

0

No Research Group Connected

Bibliographies

25

1 Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.

2 Circulating tumor cells before and during follow-up after breast cancer surgery.

3 Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial.

4 IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

5 An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein.

6 Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.

7 Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation.

8 Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application.

9 development and application of an hplc method for erlotinib protein binding studies

10 feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a phase ii trial

11 phase ii trial of erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas

12 sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases

13 Interleukin-1β Induces Tissue Factor Expression in A549 Cells via EGFR-Dependent and -Independent Mechanisms

14 Joint Serum Tumor Markers Serve as survival predictive model of Erlotinib in the treatment of recurrent Non-small Cell Lung Cancer

15 Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

16 Co-delivery of erlotinib and doxorubicin by MoS<inf>2</inf> nanosheets for synergetic photothermal chemotherapy of cancer

17 quantitative analysis of [11c]-erlotinib pet demonstrates specific binding for activating mutations of the egfr kinase domain

18 sustained response of a clivus chordoma to erlotinib after imatinib failure

19 erlotinib na segunda linha de tratamento do cancro do pulmÃ£o de nÃ£o pequenas cÃ©lulas â caso clÃnico

20 avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células an economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer

21 erlotinib no tratamento de segunda linha do cancro do pulmÃ£o de nÃ£o pequenas cÃ©lulas. caso clÃnico

22 erlotinib-associated acute pneumonitis: report of two cases

23 yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts

24 erlotinib e metástases cerebrais

25 ezrin enhances egfr signaling and modulates erlotinib sensitivity in non–small cell lung cancer cells